Scientific Annual Report 2019

Total Page:16

File Type:pdf, Size:1020Kb

Scientific Annual Report 2019 Scientific Annual Report 2019 Scientific Annual Report 2019 Contents 2 Introduction 14 Board members Director of Research 18 Group leaders 18 Neil Aaronson 37 Kees Jalink 56 Hein te Riele 19 Reuven Agami 38 Jos Jonkers 57 Lonneke van de Poll 20 Leila Akkari 39 Marleen Kok 58 Winette van der Graaf 21 Regina Beets-Tan 40 Pia Kvistborg and Olga Husson 22 Roderick Beijersbergen 41 Tineke Lenstra 60 Uulke van der Heide 23 Jos Beijnen 42 Sabine Linn 61 Michiel van der Heijden 24 André Bergman 43 René Medema 62 Wim van Harten 25 René Bernards 44 Gerrit Meijer and 63 Flora van Leeuwen and 26 Christian Blank Remond Fijneman Matti Rookus 27 Eveline Bleiker 46 Daniel Peeper 65 Fred van Leeuwen 28 Gerben Borst 47 Anastassis Perrakis 66 Maarten van Lohuizen 29 Thijn Brummelkamp 48 Benjamin Rowland 67 Jacco van Rheenen 30 Karin de Visser 49 Sanne Schagen 68 Bas van Steensel 31 Elzo de Wit 50 Alfred Schinkel 69 Olaf van Tellingen 32 William Faller 51 Marjanka Schmidt 70 Emile Voest 33 John Haanen 52 Ton Schumacher 71 Jelle Wesseling 34 Hugo Horlings 53 Titia Sixma 72 Lodewyk Wessels 35 Heinz Jacobs 54 Jan-Jakob Sonke 73 Lotje Zuur 36 Jacqueline Jacobs 55 Arnoud Sonnenberg 74 Wilbert Zwart 78 Division of 84 Division of 90 Division of Diagnostic Oncology Medical Oncology Surgical Oncology 96 Division of 102 Division of 110 Technology Radiation Oncology Pharmacology Transfer Office and Biometrics 112 Research Facilities 126 Education in 134 Clinical Oncology trials 164 Invited 166 Research 194 Personnel speakers projects index Netherlands Cancer Institute Plesmanlaan 121 1066 CX Amsterdam The Netherlands www.nki.nl Scientific Annual Report 2019 Introduction It is my pleasure to present the 2019 Scientific Annual Report of the Netherlands Cancer Institute. In it, we hope to convey how we have contributed to improving the prospects Director of Research of cancer patients by integrating state-of-the-art fundamental research, translational René Medema research, and clinical research. When I sat down to write these introductory words, I found it as difficult as each year to select just a few research highlights out of the many, with the aim of giving an idea of what we have learned and accomplished in 2019. We have all worked so hard, published beautiful papers or started or finished innovative clinical trials. But then I pictured the last or penultimate slide of all our PowerPoint presentations: the one in which we acknowledge all the people who have contributed to our project. And once again I realized the importance of collaboration in cancer research. Here are some examples of our collaborative efforts in 2019. Collaboration between the lab and the clinic is part and parcel of daily life in our Comprehensive Cancer Centre, in which some 45 nationalities are represented. In 2019, this collaboration between individual researchers and oncologists has again resulted in new insights into the mechanisms of cancer and into new patient impact. Since the summer of 2019, all oncologists within our hospital have been participating in a new clinical study in which we investigate, as the first hospital in the world and in collaboration with the Hartwig Medical Foundation, whether whole genome sequencing of tumour DNA can be implemented in standard cancer diagnostics. Our lab and clinic also closely collaborate with our pharmacy. In 2019, we have been building a brand new pharmaceutical centre equipped with innovative facilities that include clean rooms for developing advanced cellular therapies. When this becomes operative, it will lead to an even more fruitful integration of our research labs, our clinical research and our pharmacy. In 2019, the NKI and the Dutch Cancer Society designed a new cooperation agreement, covering the next five years. It devotes an annual €16.8 million for research at the Netherlands Cancer Institute. The link between the Dutch Cancer Society and the Netherlands Cancer Institute is a strong one and goes back to 1951. The fact that the Dutch Cancer Society is supporting us for another five years with this level of funding attests to their strong confidence in our work. In the years to come we will be working towards three common goals: making the results of scientific research accessible to patients more quickly, making both new and existing drugs more readily available, and improving the quality of life of everyone facing cancer or dealing with its aftermath. We also highly cherish our collaboration with all Dutch universities, including their medical centres, where the vast majority of our group leaders have a chair. In 2019, in their inaugurals, our recently appointed professors presented exciting plans for multidisciplinary collaboration with their university colleagues, aimed at generating new knowledge not only about cancer but also about other diseases, new methodologies and technologies, or about the human immune system. Many of our group leaders are also affiliated with the Oncode Institute, which unites top cancer research groups within the Netherlands and enables new collaboration in various domains. In November 2019, for instance, our institute hosted the launch of the Patient Perspective Program, which connects patients and cancer survivors to Oncode labs or individual Oncode researchers. This should decrease the distance between Oncode 2 researchers and patients so they can explore, investigate and understand each other’s worlds. Clinical research has always been impossible without collaboration with many professional partners, including pharmaceutical companies, health insurance companies, health care authorities, policy makers and thousands of patients. Collaboration has always been key in large randomized studies, but it is also becoming increasingly important in generating critical mass in innovative studies aimed at personalized medicine. These are studies with small cohorts of patients who often have rare molecular tumour profiles. At the European level, Cancer Core Europe, in which seven leading cancer centers, including the NKI, have joined forces, is a case in point. Within the EU, preparations for Horizon Europe, the next Research and Innovation Framework Programme, are in full swing. We are proud and happy that Regina Beets- Tan, head of our Radiology department, has been selected by the European Commission to be a member of Horizon Europe’s Mission Board for Cancer. Also, by working together in EU-LIFE with 13 other leading life science institutes, we can raise a powerful voice to convince the European Commission of the importance of fundamental research for the future health and well-being of Europe and its citizens. Close collaboration is also required at a global level and our research groups collaborate with other groups all over the world. In 2019, the NKI signed a declaration of intent for collaboration in clinical research with the Sun Yat-sen University Cancer Centre, which is one of best comprehensive cancer centres in China. The year before, the Netherlands Cancer Institute already signed a collaboration agreement with the Renji Hospital in Shanghai for the training of postdocs. In the Netherlands, average five-year survival rates for cancer have been rising by 1% over the past years, and the percentage of patients alive five years after diagnosis is now 65%, according to the Netherlands Cancer Registry. This is good news. Journalists often ask us whether, at a certain point in time, we will have ‘conquered’ cancer or have made it into a chronic disease. Our oncologists, who know from day- to-day experience that there are still many patients they cannot help, tend to be very modest. We also know that cancer will always be part of life, in an ageing society. FIGURE 1 CORE RESEARCH FUNDING THE NETHERLANDS CANCER INSTITUTE - ANTONI VAN LEEUWENHOEK HOSPITAL BY THE DUTCH CANCER SOCIETY AND THE MINISTRY OF HEALTH, WELFARE AND SPORT IN THE PERIOD 2007-2018 IN MILLION EUROS. 30 2012 2013 2014 2015 2016 2017 2018 2019 2011 2008 2009 2010 25 20 15 10 5 0 DUTCH CANCER SOCIETY MINISTRY OF HEALTH, WELFARE & SPORT* TOTAL * EXCLUDED ARE THE REIMBURSEMENTS FOR INTEREST AND DEPRECIATION OF BUILDINGS 3 And unfortunately, survival rates for certain cancers, such as ovarian and pancreas cancer are still depressingly low. And yet, in the Netherlands Cancer Institute, we believe that cancer need not be a terminal disease. We believe that within decades, cancer will have become a chronic disease that can be controlled, with good quality of life for the patients. We dare express this vision because we, as a global research community, are making steady progress in understanding the biology of cancer and in exploiting its Achilles heels. I am convinced that there are many more fundamental and practice-changing breakthroughs to come that will sooner or later benefit individual patients all over the world. However, whether we will be able to realize our vision partly depends on public investment in basic, curiosity-driven research. As I already mentioned, in 2019, the European Commission established the Mission Board for Cancer, as one of five mission boards established to help us solve our generation’s biggest challenges. This was a wise decision, in our opinion. But real health impact is not sustainable without strong and continued support for research aimed at understanding the fundamental mechanisms behind health and disease. Together with our partner institutes in EU-LIFE, we work hard to get this message along in Brussels. I end by thanking all our employees and everyone who supported us and collaborated with us in 2019. Since the foundation of the Netherlands Cancer Institute in 1913, we have received enormous support and commitment from our employees, volunteers and sponsors. I thank Tom de Swaan, who retired as chair of our supervisory board in 2019 and I welcome his successor Lodewijk Hijmans van den Bergh. I also want to thank the Dutch Cancer Society for their renewed institutional support and the Ministry of Health, Welfare and Sport for their substantial core funding.
Recommended publications
  • Polatuzumab Vedotin - R/R DLBCL RG7769 PD1-TIM3 Bimab - Solid Tumors NSCLC RG7446 Tecentriq – Her2-Pos
    Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) 1 Changes to the development pipeline FY 2018 update New to phase I New to phase II New to phase III New to registration 3 NMEs: 2 NMEs transitioned from Ph1 1 NME transitioned from Ph2: 2 NMEs + 1 AI transitioned from Ph2 RG6217 - HBV RG7906 - psychiatric disorders RG6042 HTT ASO - Huntington’s following filing in EU and US: RG6237 - neuromuscular disorders RG6058 tiragolumab + Tecentriq - 6 AIs: RG7596 polatuzumab vedotin - r/r DLBCL RG7769 PD1-TIM3 biMAb - solid tumors NSCLC RG7446 Tecentriq – Her2-pos. BC neoadj RG6268 entrectinib - NSCLC ROS1+ 1 AI: 1 NME starting Ph2 RG7446 Tecentriq – high risk NMIBC RG6268 entrectinib – NTRK1 pan-tumor RG7601 Venclexta + gilteritinib – r/r RG6180 iNeST (personalized cancer RG6152 Xofluza - influenza hosp. patients 3 AIs transitioned from Ph3 following AML vaccine) + pembrolizumab - malignant RG6152 Xofluza – influenza pediatric filing in EU and US: melanoma patients RG7446 Tecentriq + nab-paclitaxel 1L 1 NME following termination of Ph3 RG7601 Venclexta - r/r MM t(11:14) non sq NSCLC RG7412 crenezumab – familial RG7601 Venclexta + HMA/LDAC - 1L RG7446 Tecentriq + nab-paclitaxel Alzheimer’s disease healthy individuals AML* 1LTNBC RG7446 Tecentriq + chemo - 1L extensive 1 AI: stage SCLC RG7446 Tecentriq SC – NSCLC Removed from phase I Removed from phase II Removed from phase III Removed from registration 2 NMEs:
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Roche Template
    Changes to the development pipeline Q3 2020 update New to phase I New to phase II New to phase III New to registration 7 NMEs: 2 NMEs: 4 NMEs: 1 NME: RG6091 UBE3A LNA - Angelman syndrome RG7992 FGFR1 x KLB - NASH RG6107 crovalimab - PNH RG6396 Gavreto (pralsetinib) - RET fusion- RG6286 NME - colorectal cancer CHU Oncolytic Type 5 adenovirus - esophageal RG6413+RG6412 REGN-COV2 - SARS-CoV-2 positive NSCLC RG6315 NME - systemic sclerosis cancer prophylaxis RG6330 KRAS G12C - KRAS-mutant solid tumors RG6171 SERD(3) ER+/HER2 - metastatic breast 2 AIs: RG6418 NLRP3 inhibitor - inflammation 5 AIs: cancer RG3648 Xolair - asthma home use 4D-MT 4D-R125 - X-linked retinitis pigmentosa RG6171 SERD(3) - neoadjuvant HR+ breast 7 AIs: RG6396 Gavreto (pralsetinitb) - RET-mutant CHU CD137 agonist switch antibody - solid tumors cancer RG6058 tiragolumab+Tecentriq - stage III medullary thyroid cancer (MTC) RG6413+RG6412 REGN-COV2 - COVID-19+ unresectable 1L NSCLC 2 AIs: adult – ambulatory RG6058 tiragolumab+Tecentriq - locally adv RG7440 ipatasertib+Tecentriq - prostate cancer RG6413+RG6412 REGN-COV2 - COVID-19+ esophageal cancer previously treated with androgen receptor-targeted adult – hospitalized RG6321 PDS with ranibizumab - diabetic therapy retinopathy RG7446 Tecentriq+Venclexta - maintenance 1L RG7159 Gazyva - lupus nephritis ES-SCLC RG7601 Venclexta - 1L MDS RG7446 Tecentriq+cabozantinib - adv RCC RG7446 Tecentriq+cabozantinib - 2L NSCLC Removed from phase I Removed from phase II Removed from phase III Approvals 2 NMEs: 2 AIs: 3 AIs: 3 NMEs approved
    [Show full text]
  • The Angiopoietin-2 and TIE Pathway As a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer
    International Journal of Molecular Sciences Review The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer Alessandra Leong and Minah Kim * Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA; afl[email protected] * Correspondence: [email protected] Received: 26 September 2020; Accepted: 13 November 2020; Published: 18 November 2020 Abstract: Despite significant advances made in cancer treatment, the development of therapeutic resistance to anticancer drugs represents a major clinical problem that limits treatment efficacy for cancer patients. Herein, we focus on the response and resistance to current antiangiogenic drugs and immunotherapies and describe potential strategies for improved treatment outcomes. Antiangiogenic treatments that mainly target vascular endothelial growth factor (VEGF) signaling have shown efficacy in many types of cancer. However, drug resistance, characterized by disease recurrence, has limited therapeutic success and thus increased our urgency to better understand the mechanism of resistance to inhibitors of VEGF signaling. Moreover, cancer immunotherapies including immune checkpoint inhibitors (ICIs), which stimulate antitumor immunity, have also demonstrated a remarkable clinical benefit in the treatment of many aggressive malignancies. Nevertheless, the emergence of resistance to immunotherapies associated with an immunosuppressive tumor microenvironment has restricted therapeutic response, necessitating the development of better therapeutic strategies to increase treatment efficacy in patients. Angiopoietin-2 (ANG2), which binds to the receptor tyrosine kinase TIE2 in endothelial cells, is a cooperative driver of angiogenesis and vascular destabilization along with VEGF. It has been suggested in multiple preclinical studies that ANG2-mediated vascular changes contribute to the development and persistence of resistance to anti-VEGF therapy.
    [Show full text]
  • PD-1 / PD-L1 Combination Therapies
    PD-1 / PD-L1 Combination Therapies Jacob Plieth & Edwin Elmhirst – May 2017 Foreword Sprinkling the immuno-oncology dust When in November 2015 EP Vantage published its first immuno- oncology analysis we identified 215 studies of anti-PD-1/PD-L1 projects combined with other approaches, and called this an important industry theme. It is a measure of how central combos have become that today, barely 18 months on, that total has been blown out of the water. No fewer than 765 studies involving combinations of PD-1 or PD-L1 assets are now listed on the Clinicaltrials.gov registry. This dazzling array owes much to the transformational nature of the data seen with the first wave of anti-PD-1/PD-L1 MAbs. It also indicates how central combinations will be in extending immuno-oncology beyond just a handful of cancers, and beyond certain patient subgroups. But the combo effort is as much about extending the reach of currently available drugs like Keytruda, Opdivo and Tecentriq as it is about making novel approaches viable by combining them with PD-1/PD-L1. On a standalone basis several of the industry’s novel oncology projects have underwhelmed. As data are generated it will therefore be vital for investors to tease out the effect of combinations beyond that of monotherapy, and it is doubtful whether the sprinkling of magic immuno-oncology dust will come to the rescue of substandard products. This is not stopping many companies, as the hundreds of combination studies identified here show. This report aims to quantify how many trials are ongoing with which assets and in which cancer indications, as well as suggesting reasons why some of the most popular approaches are being pursued.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • First-In-Human Phase I Study of Single-Agent Vanucizumab, a First-In
    Author Manuscript Published OnlineFirst on December 7, 2017; DOI: 10.1158/1078-0432.CCR-17-1588 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Hidalgo et al. Clin Cancer Res submission 2017 First-in-human phase I study of single-agent vanucizumab, a first-in- class bi-specific anti-angiopoietin-2/anti-VEGF antibody, in adult patients with advanced solid tumors Manuel Hidalgo1,2*; Maria Martinez Garcia3*; Christophe Le Tourneau4; Christophe Massard5; Elena Garralda2; Valentina Boni2; Alvaro Taus3; Joan Albanell3; Marie-Paule Sablin4; Marie Alt4; Ratislav Bahleda5; Andrea Varga5; Christophe Boetsch6; Izolda Franjkovic7; Florian Heil7; Angelika Lahr7; Katharina Lechner7; Anthony Morel6; Tapan Nayak6; Simona Rossomanno6; Kevin Smart8; Kay Stubenrauch7; Oliver Krieter7. *Joint first authors 1Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain. 2START Madrid-CIOCC, HM Sanchinarro.3Medical Oncology Department, Hospital del Mar. Barcelona, Spain.4Department of Medical Oncology, Institut Curie, Saint-Cloud & Paris.5Department of Drug Development, Gustave Roussy, Villejuif, France.6Roche Innovation Center Basel, Basel, Switzerland.7Roche Innovation Center Munich, Penzberg, Germany.8Roche Innovation Centre Welwyn, Welwyn Garden City, United Kingdom. Running title: Phase I study of vanucizumab Keywords: Vanucizumab, RG7221, RO5520985, VEGF-A, Ang-2 Corresponding authors: 1 Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 7, 2017; DOI: 10.1158/1078-0432.CCR-17-1588 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Hidalgo et al. Clin Cancer Res submission 2017 Manuel Hidalgo, Chief, Division Hematology Oncology, Director, Rosenberg Clinical Cancer Center, Beth Israel Deaconess Medical Center, Member of the Faculty of Medicine, Harvard Medical School, 330 Brookline Avenue - KS207, Boston, MA 02215, USA.
    [Show full text]
  • Gdzie Zginął „Antek Rozpylacz”
    68 MIEJSCA Z HISTorią Gdzie zginął „Antek Rozpylacz” Katarzyna Dzierzbicka W Alejach Jerozolimskich w Warszawie, tuż obok sklepu „Vitkac”, wisi czarna tablica upamiętniająca „Antka Rozpylacza”. Wyryty na niej napis jest jednak mylący. Antoni Godlewski zginął około 300 metrów dalej. Miał 21 lat i nie był studentem medycyny. ntoni Szczęsny Godlew- rzony w 1944 roku. Szkoła Powszechna ski urodził się w Warsza- Towarzystwa Ziemi Mazowieckiej to wie 11 stycznia 1923 roku. dziś Gimnazjum i Liceum im. Narcy- Był synem Franciszka zy Żmichowskiej. W 1937 roku ojciec AGodlewskiego – wysokiego urzędni- przeniósł Antoniego do Zakładu Nauko- ka państwowego II RP, w latach 1927– wo-Wychowawczego Ojców Jezuitów –1933 wicewojewody nowogródzkiego, w Chyrowie koło Przemyśla, dziś leżą- 1934–1937 wicewojewody warszaw- cym na terenie Ukrainy. Askiego i 1937–1939 starosty powiatu warszawskiego. Po powrocie z Nowo- Łowca snajperów gródka Franciszek i Aniela Godlew- W czasie okupacji Antoni Godlew- Dzierzbicka Katarzyna Fot. scy wraz z synem ponownie zamiesz- ski studiował na Tajnej Politechnice kali w Warszawie, w al. Przyjaciół 3a. Warszawskiej. Omyłkowa informacja W 1942 roku rodzina została wyrzucona z tablicy pamiątkowej o studiach me- plutonowy podchorąży batalionu „So- z mieszkania przez Niemców. Państwo dycznych wzięła się najprawdopodob- kół”. Jego wspomnienia, jak również Godlewscy przenieśli się na ul. Mar- relacje pozostałych cytowanych prze- szałkowską 91 m. 19. Budynek ten zo- ze mnie kolegów „Antka Rozpylacza” stał zniszczony w czasie wojny. Dziś z czasów II wojny światowej, zostały w jego miejscu stoi biurowiec. Zbu- utrwalone na taśmach Archiwum Hi- dowane pod koniec lat trzydziestych storii Mówionej Muzeum Powstania XX wieku kamienice w al. Przyjaciół Warszawskiego. przetrwały za to wojenną zawieruchę.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • See Who Attended
    Company Name First Name Last Name Job Title Country 24Sea Gert De Sitter Owner Belgium 2EN S.A. George Droukas Data analyst Greece 2EN S.A. Yannis Panourgias Managing Director Greece 3E Geert Palmers CEO Belgium 3E Baris Adiloglu Technical Manager Belgium 3E David Schillebeeckx Wind Analyst Belgium 3E Grégoire Leroy Product Manager Wind Resource Modelling Belgium 3E Rogelio Avendaño Reyes Regional Manager Belgium 3E Luc Dewilde Senior Business Developer Belgium 3E Luis Ferreira Wind Consultant Belgium 3E Grégory Ignace Senior Wind Consultant Belgium 3E Romain Willaime Sales Manager Belgium 3E Santiago Estrada Sales Team Manager Belgium 3E Thomas De Vylder Marketing & Communication Manager Belgium 4C Offshore Ltd. Tom Russell Press Coordinator United Kingdom 4C Offshore Ltd. Lauren Anderson United Kingdom 4Cast GmbH & Co. KG Horst Bidiak Senior Product Manager Germany 4Subsea Berit Scharff VP Offshore Wind Norway 8.2 Consulting AG Bruno Allain Président / CEO Germany 8.2 Consulting AG Antoine Ancelin Commercial employee Germany 8.2 Monitoring GmbH Bernd Hoering Managing Director Germany A Word About Wind Zoe Wicker Client Services Manager United Kingdom A Word About Wind Richard Heap Editor-in-Chief United Kingdom AAGES Antonio Esteban Garmendia Director - Business Development Spain ABB Sofia Sauvageot Global Account Executive France ABB Jesús Illana Account Manager Spain ABB Miguel Angel Sanchis Ferri Senior Product Manager Spain ABB Antoni Carrera Group Account Manager Spain ABB Luis andres Arismendi Gomez Segment Marketing Manager Spain
    [Show full text]
  • Last Name First Name Middle Name First Paper Second Paper
    LAST NAME FIRST NAME MIDDLE NAME FIRST PAPER SECOND PAPER Mikoligczik Jacob V10, P452 Mikoligzik Jacob V21, P163 Mikotcyczik Jacob V10, P452 Milanesi Battista B1, F3, P413 Milanesi Battista B1, F3, P413 Milanesi Vincenzo V15, P866 Milanesi Vincenzo V11, P113 Milanovic Cazo B3, F3, P2213 Milanovich Caszo B6, F2, P2406 Milanovich Louis B3, F3, P2213 Milanovich Louis B6, F2, P2406 B6, F2, P2406 Milansesi Battista V26, P32 V26, P32 Milbouw Petrus V16, P465 Milbowv Petrus V16, P465 Milcki George V10, P293 Mild Theodore V12, P410 Milik Victor B6, F3, P2468 Milik Vinko B3, F3, P2277 Milik Vinko B6, F3, P2468 B6, F3, P2468 Miliotis Stamatis B2, F1, P237 Miller Christian V12, P342 Miller Christian V14, P365 Miller Frank V8, P204 Miller Frank V13, P636 Miller Frank V15, P725 Miller George V8, P139 Miller George H. V12, P397 Miller George H. V14, P423 Miller Martin V8, P494 Miller Norman V17, P86 Thursday, August 05, 2004 Page 351 of 568 LAST NAME FIRST NAME MIDDLE NAME FIRST PAPER SECOND PAPER Miller Rudolph Th. V12, P161 Miller Rudolph Th. V14, P175 Millie Mario V10, P186 Milligan Patrick V22, P195 V22, P195 Millman Alexander V14, P8 Millonig John V12, P435 Millonig John V14, P465 Millouw Petrus V10, P203 Milman Alexander V12, P5 Minapace Ignazia V12, P52 Minelli Filippo V9, P130 Minelli French V10, P130 Minelli Paele V9, P130 Minelli Pompilio V9, P124 Minenko Finarci B3, F3, P2291 Minenko Finarci B6, F3, P2494 Minenko Harry B3, F3, P2291 Minenko Harry B6, F3, P2494 B6, F3, P2494 Miners Edward Francis V25, P7 V25, P7 Miners George Alfred V26, P57
    [Show full text]